Clinical trials: Non-Small Cell Lung
Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or…
- Trial name
- NCT00095225
- Testing
- Avastin (bevacizumab), Tarceva (erlotinib HCl)
- Where
- 48 sites in United States
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Lung Cancer (NSCLC)
Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC
This study will investigate the relationship between respiratory and gut microbiome and PD-1/PD-L1 immune checkpoint inhibitor efficacy and immune-related adverse events (irAE) in patients with non-small cell lung cancer (Stage…
- Trial name
- NCT06613308
- Testing
- Neoadjuvant immunotherapy combined with chemotherapy, Neoadjuvant chemotherapy
- Volunteers
- 20 people
- Sponsor
- Capital Medical University
Prophylactic Cranial Irradiation, Cumulative Incidence of Brain Metastases
Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical Study
Lung cancer has remained the leading cause of cancer-related deaths worldwide. An important and frequent cause of morbidity in this patient group is the development of brain metastases (BM).
- Trial name
- NCT06014450
- Testing
- Prophylactic Cranial Irradiation for experiment arm
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Guizhou Medical University
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Non-Small-Cell Lung Carcinoma
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
Phase II, randomised, controlled, non comparative study with 2 parallel groups: Arm A: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemotherapy including 2 cycles of…
- Trial name
- NCT00985855
- Testing
- cisplatin, vinorlebine, cetuximab, cisplatine, etoposide, cetuximab
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Institut de Cancérologie de la Loire
Non-Small Cell Lung Cancer
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR
A Phase III, multicenter, open-label, randomized trial of Erlotinib (Tarceva®) versus chemotherapy in patients with advanced NSCLC with mutations in the Tyrosine Kinase (TK) domain of the EGFR.
- Trial name
- EURTAC (NCT00446225)
- Testing
- Erlotinib, Carboplatin, Gemcitabin
- Where
- 76 sites in France, Italy and 1 more
- Volunteers
- 174 people
- Sponsor
- Spanish Lung Cancer Group
Carcinoma, Non-Small-Cell-Lung
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
The purpose of this study is to evaluate the safety of I-PDT with Temoporfin for patients with Non-Resectable Non-Small-Cell Lung Cancer (NR-NSCLC).
- Trial name
- NCT01637376
- Testing
- Temoporfin
- Where
- United States
- Sponsor
- University of Arkansas
Non-Small Cell Lung Cancer
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that…
- Trial name
- NSCLC (NCT06928389)
- Testing
- Ivonescimab, docetaxel
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Akeso
Lung Cancer, Nonsmall Cell
Plasmodium Immunotherapy for Lung Cancer
The objective of this study is to evaluate the safety and the effectiveness of Plasmodium immunotherapy (blood-stage infection of Plasmodium vivax) for advanced non-small cell lung cancer.The treatment will last 3-6 months from…
- Trial name
- NCT02786589
- Testing
- Blood-stage infection of P. vivax
- Where
- China
- Volunteers
- 30 people
- Sponsor
- State Key Laboratory of Respiratory Disease
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung…
- Trial name
- NCT04216316
- Testing
- Berzosertib, Biospecimen Collection, Carboplatin
- Where
- 34 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Non Small Cell Lung Cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer…
- Trial name
- TROPION-Lung08 (NCT05215340)
- Testing
- Datopotamab Deruxtecan, Pembrolizumab
- Where
- 234 sites in United States, Argentina and 26 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Lung Cancer
Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Bexarotene and tretinoin may cause tumor cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as cisplatin, carboplatin, docetaxel, and capecitabine, work in…
- Trial name
- NCT00514293
- Testing
- bexarotene, capecitabine, carboplatin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Raghu Nandan, M.D., Inc
Carcinoma, Non-Small-Cell Lung
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy.
- Trial name
- NCT01523587
- Testing
- afatinib, erlotinib
- Where
- 192 sites in United States, Argentina and 21 more
- Volunteers
- 795 people
- Sponsor
- Boehringer Ingelheim
Adjuvant, Chemotherapy
Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC
There are limited numbers of retrospective studies showing the effectiveness of adjuvant chemotherapy over observation in resected lung cancers.
- Conditions
- Adjuvant, Chemotherapy, Lung, Cancers
- Trial name
- NCT00484016
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
ELDERLY PEOPLE, Non-small Cell Lung Cancer
A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.
Management of lung cancer remains very controversial for elderly patients (pts) and they are often excluded from clinical trials.
- Trial name
- NCT00198406
- Testing
- diagnostic and therapeutic management
- Where
- France
- Volunteers
- 1,653 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
SMARCA4-Deficient Tumor, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
This single-arm, open-label, Phase II study assesses first-line QL1706 (iparomlimab and tuvonralimab, an anti-PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy to treat patients with treatment-naïve…
- Trial name
- QL1706 (NCT07200947)
- Testing
- QL1706, nab-paclitaxel, carboplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhijie Wang
Non Small Cell Lung Cancer
Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer
Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have been conducted with success on Melanoma and glioblastoma.
- Trial name
- NCT04397926
- Testing
- Individualized neoantigen peptides vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer, Ovarian Cancer
Continued Access to RXDX-105
This study is being done to see if people with Non-Small Cell Lung Cancer (NSCLC) or ovarian cancer benefit from continued treatment with the study drug, RXDX-105.
- Conditions
- Non Small Cell Lung Cancer, Ovarian Cancer, RET Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT03784378
- Testing
- RXDX-105
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006378
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study.
- Trial name
- NCT02770014
- Testing
- Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.